JAK inhibitors target senescent cells in aging study

Researchers at the Mayo Clinic say that inhibiting certain enzyme pathways in cells cut down on inflammation and reduced frailty, a pathway that could play a significant role in antiaging therapies. The researchers used JAK inhibitors to do the work in "senescent" cells linked to aging. "Our goal is not necessarily to increase life span, and certainly not life span at all costs. Our goal is to enhance health span--the period during life when people are independent," explains James Kirkland, director of the Mayo Clinic Robert and Arlene Kogod Center on Aging. "This drug approach and others we are developing look like they might hold some promise in reaching that goal." Release